|
Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer Clinical research trials and Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer. Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer clinical trial. Human subjects often get the best healthcare possible for their Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer  Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer
Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer
For Condition: adenocarcinoma of the colon,adenocarcinoma of the rectum,Stage 4 rectal cancer,stage 4 colon cancer
Status: Recruiting
Sponsor(s): EORTC Gastrointestinal Tract Cancer Cooperative Group ,
Synopsis: RATIONALE: Drugs used in chemotherapy such as irinotecan, capecitabine, leucovorin, and fluorouracil use different ways to stop tumor cells from dividing so they stop growing or die. Celecoxib may stop the growth of colorectal cancer by stopping blood flow to the tumor. It is not yet known which combination chemotherapyregimen with or without celecoxib is more effective in treating metastatic colorectal cancer. PURPOSE: Randomizedphase III trial to compare the effectiveness of two combination chemotherapy regimens with or without celecoxib in treating patients who have metastatic colorectal cancer.
Details: OBJECTIVES: - Compare the progression-free survival of patients with metastatic colorectal cancer treated with capecitabine and irinotecan vs fluorouracil, leucovorin calcium, and irinotecan with vs without celecoxib. - Compare the safety of these regimens in these patients. - Compare the response rate in patients treated with these regimens. - Compare the time to treatment failure and overall survival of patients treated with these regimens. OUTLINE: This is a randomized, double-blind*, multicenter study. Patients are stratified according to participating center, prior adjuvant therapy (yes vs no), and risk group (poor vs intermediate vs good). Patients are randomized to 1 of 4 treatment arms. - Arm I: Patients receive irinotecan IV over 30-90 minutes on days 1 and 22; oral capecitabine twice daily on days 1-15 and 22-36; and oral celecoxib twice daily on days 1-42. - Arm II: Patients receive irinotecan and capecitabine as in arm I and oral placebo twice daily on days 1-42. - Arm III: Patients receive irinotecan IV over 30-90 minutes on days 1, 15, and 29; leucovorin calcium (CF) IV over 2 hours and fluorouracil (5-FU) IV over 22 hours on days 1, 2, 15, 16, 29, and 30; and oral celecoxib twice daily on days 1-42. - Arm IV: Patients receive irinotecan, CF, and 5-FU as in arm III and oral placebo twice daily on days 1-42. In all arms, treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. If all chemotherapy is discontinued due to toxicity, patients may continue celecoxib or placebo until disease progression, unacceptable toxicity, or starting a new cytotoxic regimen. NOTE: *The double-blind treatment only applies to the celecoxib and placebo randomization Patients are followed every 2 months. PROJECTED ACCRUAL: A total of 692 patients (173 per treatment arm) will be accrued for this study within 3.5 years.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed adenocarcinoma of the colon or rectum - Metastatic disease - Measurable disease - Patients who received prior radiotherapy must have measurable or evaluable disease outside the radiotherapy field - No CNS metastases PATIENT CHARACTERISTICS: Age - 18 and over Performance status - WHO 0-2 Life expectancy - Not specified Hematopoietic - WBC at least 3,000/mm^3 - Platelet count at least 100,000/mm^3 Hepatic - Bilirubin no greater than 2 times upper limit of normal (ULN) - AST and ALT no greater than 2.5 times ULN (5 times ULN in the presence of liver metastases) Renal - Creatinine clearance at least 51 mL/min - No severe renal impairment Cardiovascular - No severe cardiac disease - No uncontrolled angina pectoris - No myocardial infarction within the past 6 months Other - Not pregnant or nursing - Fertile patients must use effective contraception during and for 6 months after study participation - No active Crohn's disease - No other malignancy except adequately treated carcinoma in situ of the cervix or nonmelanoma skin cancer - No other uncontrolled severe medical condition - No psychological, familial, sociological, or geographical condition that would preclude study compliance and follow-up PRIOR CONCURRENT THERAPY: Biologic therapy - No concurrent active or passive immunotherapy for colon cancer Chemotherapy - No prior chemotherapy for metastatic disease Endocrine therapy - Not specified Radiotherapy - See Disease Characteristics - At least 4 weeks since prior radiotherapy - No concurrent radiotherapy Surgery - Not specified Other - At least 6 months since prior adjuvant therapy - More than 4 weeks since prior investigational drugs - No concurrent sorivudine or chemically related analogues (e.g., brivudine) - No other concurrent investigational drugs - No other concurrent cytotoxic agents - No concurrent prophylactic fluconazole - No concurrent or planned cyclo-oxygenase-2 (COX-2) inhibitors or nonsteroidal anti-inflammatory drugs - No concurrent chronic use of full-dose aspirin (325 mg/day or greater) - Concurrent low-dose (cardioprotective) aspirin prophylaxis (no more than 325 mg every other day OR no more than 162.5 mg per day) allowed
Total Enrollment:
Location and Contact Information:
Overall Study Official:
Claus-HenningKoehne, , Medizinische Klinik I
Algemeen Ziekenhuis Middelheim *Recruiting*
Antwerp, , 2020
Belgium
Recruiting Contact Person 32-3-280-3111
Additional Information:
Study ID Numbers: CDR0000309572; EORTC-40015
Study Start Date:
Record last reviewed: June 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00064181
Other Stage 4 Rectal Cancer Studies:
1. Erlotinib in Treating Patients With Recurrent or Metastatic Colorectal Cancer
2. Neoadjuvant Radiation Therapy and Capecitabine in Treating Patients With Stage III or Stage IV Colorectal Adenocarcinoma
3. Combination Chemotherapy in Treating Patients With Colorectal Cancer
4. Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients With Metastatic Colorectal Cancer
5. Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
Related Studies:
Other Stage 4 rectal cancer Clinical Trials
Other Clinical Trials
Other Antwerp Clinical Trials
Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer
|
|
|
|
|
|
|
|
